Mechanism of ancrod anticoagulation
Authors:
- Salvatore V. PizzoSPSalvatore V. Pizzo
- Martin L. SchwartzMSMartin L. Schwartz
- Robert L. HillRHRobert L. Hill
- Patrick A. McKeePMPatrick A. McKee
Open Access
- 1 November 1972
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 51 (11) , 2841-2850
Abstract
Fibrin formed in response to ancrod, reptilase, or thrombin was reduced by beta-mercaptoethanol and examined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. It was found that ancrod progressively and totally digested the alpha-chains of fibrin monomers at sites different than plasmin; however, further digestion of fibrin monomers by either reptilase or thrombin was not observed. Highly purified ancrod did not activate fibrin-stabilizing factor (FSF); however, the reptilase preparation used in these experiments, like thrombin, activated FSF and thereby promoted cross-link formation. Fibrin, formed by clotting purified human fibrinogen with ancrod, reptilase, or thrombin for increasing periods of time in the presence of plasminogen, was incubated with urokinase and observed for complete lysis. Fibrin formed by ancrod was strikingly more vulnerable to plasmin digestion than was fibrin formed by reptilase or thrombin. The lysis times for fibrin formed for 2 hr by ancrod, reptilase, or thrombin were 18, 89, and 120 min, respectively. Evidence was also obtained that neither ancrod nor reptilase activated human plasminogen. These results indicate that fibrin formed by ancrod is not cross-linked and has significantly degraded alpha-chains: as expected, ancrod-formed fibrin is markedly susceptible to digestion by plasmin.Keywords
This publication has 40 references indexed in Scilit:
- Molecular Weight Studies on Human Plasminogen and Plasmin at the Microgram LevelJournal of Biological Chemistry, 1969
- The Effect of Arvin on Blood Coagulation FactorsBritish Journal of Haematology, 1968
- ANTICOAGULANT THERAPY WITH A PURIFIED FRACTION OF MALAYAN PIT VIPER VENOMThe Lancet, 1968
- THERAPEUTIC DEFIBRINATION IN THE TREATMENT OF THROMBOTIC DISEASEThe Lancet, 1968
- THE PARADOX IN THERAPEUTIC DEFIBRINATIONThe Lancet, 1968
- PHARMACOLOGY AND TOXICOLOGY OF A DEFIBRINATING SUBSTANCE FROM MALAYAN PIT VIPER VENOMThe Lancet, 1968
- EXPERIMENTAL PRODUCTION OF MICROANGIOPATHIC HÆMOLYTIC ANÆMIA IN VIVOThe Lancet, 1967
- In vivo effects of Agkistrodon rhodostoma venom: studies with fibrinogen-131I.Journal of Clinical Investigation, 1966
- The role of the reticuloendothelial system in diffuse, low grade intravascular coagulation.1966
- A Study of the Coagulant Properties of Malayan Pit‐Viper VenomBritish Journal of Haematology, 1965